Transgene SA (LON:0OCQ)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 190.54M +150.2% |
| Revenue (ttm) | 6.29M +13.5% |
| Net Income | -32.73M |
| EPS | -0.23 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40 |
| Open | 0.8180 |
| Previous Close | 0.8230 |
| Day's Range | 0.8160 - 0.8180 |
| 52-Week Range | 0.7300 - 1.5000 |
| Beta | 0.73 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 24, 2026 |
About Transgene
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastroi... [Read more]
Financial Performance
In 2025, Transgene's revenue was 7.21 million, an increase of 13.49% compared to the previous year's 6.35 million. Losses were -37.52 million, 10.5% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Transgene Earnings release: Q1 2026
Transgene released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Transgene Earnings Call Transcript: H2 2025
Strong clinical progress in 2025 with TG4050 showing 100% disease-free survival in phase I, robust fundraising securing operations through early 2028, and preparations for new trials and manufacturing scale-up. Key data readouts and industry partnerships are anticipated in the coming years.
Transgene Annual report: H2 2025
Transgene has published its H2 2025 annual report on March 24, 2026.
Transgene Earnings release: H2 2025
Transgene released its H2 2025 earnings on March 24, 2026, summarizing the period's financial results.
Transgene Slides: H2 2025
Transgene has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 24, 2026.
Transgene Transcript: Status Update
TG4050 demonstrated 100% disease-free survival at 24 months in phase I for operable head and neck cancer, with robust, durable T cell responses and strong translational support for its mechanism. Phase II and new combination trials are progressing, with key data expected from 2026 onward.
Transgene Earnings release: Q3 2025
Transgene released its Q3 2025 earnings on November 4, 2025, summarizing the period's financial results.
Transgene Earnings Call Transcript: H1 2025
TG4050 achieved 100% disease-free survival at 24 months in phase I, with phase II progressing and key data expected through 2027. Financials are stable with funding secured to end-2026, and focus remains on the myvac platform amid a challenging biotech environment.
Transgene Quarterly report: H1 2025
Transgene has published its H1 2025 quarterly earnings report on September 16, 2025.
Transgene Earnings release: H1 2025
Transgene released its H1 2025 earnings on September 16, 2025, summarizing the period's financial results.
Transgene Slides: H1 2025
Transgene has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 16, 2025.
Transgene Slides: Corporate Presentation
Transgene has posted slides in relation to its latest quarterly earnings report, which was published on June 19, 2025.
Transgene Transcript: Status Update
Positive phase I results for TG4050 show 100% relapse-free survival at 30 months in early-stage head and neck cancer, with durable immune responses and strong safety. Phase II is ongoing, and expansion to other solid tumors is planned, supported by manufacturing scale-up and a differentiated AI-driven platform.
Transgene Press release: Status Update
Transgene issued a press release on June 6, 2025, disclosing material business information to investors.
Transgene Earnings release: Q1 2025
Transgene released its Q1 2025 earnings on April 24, 2025, summarizing the period's financial results.
Transgene Earnings Call Transcript: H2 2024
Clinical proof of concept for TG4050 was achieved, with all treated patients disease-free at 24 months. Financials are on track, with funding secured through April 2026. Key data readouts for TG4050, TG4001, BT-001, and TG6050 are expected throughout 2025.
Transgene Annual report: H2 2024
Transgene has published its H2 2024 annual report on March 27, 2025.
Transgene Earnings release: H2 2024
Transgene released its H2 2024 earnings on March 27, 2025, summarizing the period's financial results.
Transgene Slides: H2 2024
Transgene has posted slides in relation to its H2 2024 quarterly earnings report, which was published on March 27, 2025.
Transgene Slides: Corporate Presentation
Transgene has posted slides in relation to its latest quarterly earnings report, which was published on March 27, 2025.
Transgene Earnings release: Q3 2024
Transgene released its Q3 2024 earnings on November 7, 2024, summarizing the period's financial results.
Transgene Transcript: Study Update
A phase 2 trial of TG4001 plus avelumab in advanced HPV-16-positive cancers did not meet its primary endpoint, but a trend toward efficacy was observed in cervical cancer patients. Full results and further analyses will be presented in 2025.
Transgene Press release: Study Update
Transgene issued a press release on October 14, 2024, disclosing material business information to investors.
Transgene Slides: Study Update
Transgene has posted slides in relation to its latest quarterly earnings report, which was published on October 14, 2024.
Transgene Earnings Call Transcript: H1 2024
Significant clinical progress was made in immunotherapy programs, with TG4050 and TG4001 advancing in trials and strong early results reported. Financial stability is ensured through Q4 2025 after a major debt-to-equity conversion, and no R&D budget increase is planned.